Suppr超能文献

基于接受联合化疗的癌症患者的生存时间来定义和排序个体药物的效果。

Defining and ranking effects of individual agents based on survival times of cancer patients treated with combination chemotherapies.

机构信息

Department of Biostatistics, M.D. Anderson Cancer Center, Houston, TX, U.S.A..

出版信息

Stat Med. 2011 Jul 10;30(15):1777-94. doi: 10.1002/sim.4249. Epub 2011 May 17.

Abstract

An important problem in oncology is comparing chemotherapy (chemo) agents in terms of their effects on survival or progression-free survival time. When the goal is to evaluate individual agents, a difficulty commonly encountered with observational data is that many patients receive a chemo combination including two or more agents. Because agents given in combination may interact, quantifying the contribution of each individual agent to the combination's overall effect is problematic. Still, if on average combinations including a particular agent confer longer survival, then that agent may be considered superior to agents whose combinations confer shorter survival. Motivated by this idea, we propose a definition of individual agent effects based on observational survival data from patients treated with many different chemo combinations. We define an individual agent effect as the average of the effects of the chemo combinations that include the agent. Similarly, we define the effect of each pair of agents as the average of the effects of the combinations including the pair. Under a Bayesian regression model for survival time in which the chemo combination effects follow a hierarchical structure, these definitions are used as a basis for estimating the posterior effects and ranks of the individual agents, and of all pairs of agents. The methods are illustrated by a data set arising from 224 pediatric brain tumor patients treated with over 27 different chemo combinations involving seven chemo agents.

摘要

肿瘤学中的一个重要问题是比较化疗(chemo)药物在生存或无进展生存时间方面的效果。当目标是评估单个药物时,观察数据中常见的一个困难是,许多患者接受了包括两种或更多种药物的化疗联合治疗。由于联合使用的药物可能会相互作用,因此量化每个单独药物对联合治疗总体效果的贡献是有问题的。尽管如此,如果包含特定药物的联合治疗平均会延长生存时间,那么该药物可能被认为优于那些联合治疗会缩短生存时间的药物。基于这个想法,我们提出了一种基于接受许多不同化疗联合治疗的患者的观察性生存数据的单个药物效果的定义。我们将单个药物的效果定义为包含该药物的化疗联合的效果的平均值。同样,我们将每对药物的效果定义为包含该对药物的组合的效果的平均值。在一个用于生存时间的贝叶斯回归模型中,其中化疗联合效果遵循层次结构,这些定义被用作估计单个药物和所有对药物的后效和等级的基础。该方法通过来自 224 名接受过涉及 7 种化疗药物的超过 27 种不同化疗联合治疗的儿科脑肿瘤患者的数据进行说明。

相似文献

8
Pediatric choroid plexus neoplasms.小儿脉络丛肿瘤
Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):249-54. doi: 10.1016/s0360-3016(98)00560-4.
10
Chemotherapy for advanced gastric cancer.晚期胃癌的化疗
Cochrane Database Syst Rev. 2017 Aug 29;8(8):CD004064. doi: 10.1002/14651858.CD004064.pub4.

本文引用的文献

6
Choroid plexus tumours.脉络丛肿瘤
Br J Cancer. 2002 Nov 4;87(10):1086-91. doi: 10.1038/sj.bjc.6600609.
7
Bayesian information criterion for censored survival models.删失生存模型的贝叶斯信息准则。
Biometrics. 2000 Mar;56(1):256-62. doi: 10.1111/j.0006-341x.2000.00256.x.
8
Radiation therapy and survival in choroid plexus carcinoma.脉络丛癌的放射治疗与生存率
Lancet. 1999 Jun 19;353(9170):2126. doi: 10.1016/s0140-6736(99)01744-4.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验